早期类风湿关节炎达标治疗后6个月临床与超声缓解与未来良好影像学及身体结局的关联
在ARCTIC试验中,103例新诊断早期类风湿关节炎患者接受包含超声信息的达标治疗,6个月时按多种临床和超声定义评估缓解,分析其与12-24个月持续无影像学进展及良好结局的关联。ACR/EULAR布尔缓解(44关节)、超声能量多普勒无信号和灰阶缓解与无影像学进展相关,所有临床缓解标准与良好结局相关。
要点
- ACR/EULAR布尔缓解(44关节)与无影像学进展相关(OR 3.2,95%CI 1.2至8.4)。
- 超声能量多普勒无信号与无影像学进展相关(OR 3.6,95%CI 1.3至10.0)。
- 灰阶缓解与无影像学进展相关(OR 3.2,95%CI 1.2至8.0)。
核心结论
- 数据支持以44关节ACR/EULAR布尔缓解作为早期类风湿关节炎的首选治疗目标;超声无炎症与无影像学进展相关。
研究设计与样本
- ARCTIC随机试验中103例新诊断早期类风湿关节炎患者,接受包含超声信息的达标治疗策略。
主要发现
- 6个月时42%至82%患者达到缓解(取决于定义);71%患者无影像学进展,37%患者达到良好结局。
关键数值与推荐
- 6个月ACR/EULAR布尔缓解(44关节)与无影像学进展相关(OR 3.2,95%CI 1.2至8.4);超声能量多普勒与无影像学进展相关(OR 3.6,95%CI 1.3至10.0);灰阶缓解与无影像学进展相关(OR 3.2,95%CI 1.2至8.0);所有临床缓解标准(非超声)与良好结局相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore associations between remission, based on clinical and ultrasound definitions, and future good radiographic and physical outcome in early rheumatoid arthritis (RA). METHODS: Newly diagnosed patients with RA followed a treat-to-target strategy incorporating ultrasound information in the Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen (ARCTIC) trial. We defined 6-month remission according to Disease Activity Score, Disease Activity Score in 28 joints-erythrocyte sedimentation rate, American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean criteria, Simplified Disease Activity Index, Clinical Disease Activity Index and two ultrasound definitions (no power Doppler signal, grey scale score ≤2). Two outcomes were defined: no radiographic progression and good outcome (no radiographic progression+physical function≥general population median), both sustained 12-24 months. We calculated the ORs of these outcomes for the remission definitions. RESULTS: Of 103 patients, 42%-82% reached remission at 6 months, dependent on definition. Seventy-one per cent of patients had no radiographic progression and 37% had good outcome. An association between 6-month remission and no radiographic progression was observed for ACR/EULAR Boolean remission (44 joints, OR 3.2, 95% CI 1.2 to 8.4), ultrasound power Doppler (OR 3.6, 95% CI 1.3 to 10.0) and grey scale remission (OR 3.2, 95% CI 1.2 to 8.0). All clinical, but not ultrasound remission criteria were associated with achievement of a good outcome. CONCLUSIONS: Our data support ACR/EULAR Boolean remission based on 44 joints as the preferred treatment target in early RA. Absence of ultrasound inflammation was associated with no radiographic progression. TRIAL REGISTRATION NUMBER: NCT01205854; Post-results.
引用
- Paulshus Sundlisæter N, Aga AB, Olsen IC, et al. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes. Ann Rheum Dis. 2018. PMID: 29934373. doi:10.1136/annrheumdis-2017-212830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。